PDAC
Clinical trials for PDAC explained in plain language.
Never miss a new study
Get alerted when new PDAC trials appear
Sign up with your email to follow new studies for PDAC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy aims at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests an experimental drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V mutation. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 574 participants will …
Matched conditions: PDAC
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 29, 2026 04:30 UTC
-
New hope for pancreatic cancer: targeted drug trial launches
Disease control Recruiting nowThis phase 3 trial tests a new drug called daraxonrasib, alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a specific RAS gene mutation will be randomly assigned to one of three treatment groups. The study aim…
Matched conditions: PDAC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 29, 2026 04:30 UTC
-
New drug duo targets tough KRAS mutation in advanced cancers
Disease control Recruiting nowThis study tests two experimental drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific KRAS G12D gene change. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or …
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 04:29 UTC